

# Guizhen Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8511481/publications.pdf>

Version: 2024-02-01

57  
papers

44,189  
citations

249298

26  
h-index

169272

56  
g-index

61  
all docs

61  
docs citations

61  
times ranked

73920  
citing authors

#	ARTICLE	IF	CITATIONS
1	One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents. <i>Clinical Infectious Diseases</i> , 2022, 75, e1072-e1081.	2.9	48
2	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 196-208.	4.6	147
3	Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients. <i>Human Immunology</i> , 2022, 83, 119-129.	1.2	17
4	Biosafety chemistry and biosafety materials: A new perspective to solve biosafety problems. <i>Biosafety and Health</i> , 2022, 4, 15-22.	1.2	18
5	An engineered bispecific human monoclonal antibody against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 423-430.	7.0	38
6	A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women. <i>Scientific Reports</i> , 2022, 12, 6609.	1.6	10
7	An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses. <i>Biosafety and Health</i> , 2022, 4, 179-185.	1.2	1
8	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
9	Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	21
10	Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 956.	2.1	8
11	Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. <i>Nature Communications</i> , 2022, 13, .	5.8	26
12	Sustained abnormality with recovery of COVID-19 convalescents: a 2-year follow-up study. <i>Science Bulletin</i> , 2022, 67, 1556-1561.	4.3	5
13	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 39-51.	4.6	923
14	Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study. <i>Virologica Sinica</i> , 2021, 36, 1088-1092.	1.2	0
15	A Novel Potentially Recombinant Rodent Coronavirus with a Polybasic Cleavage Site in the Spike Protein. <i>Journal of Virology</i> , 2021, 95, e0117321.	1.5	16
16	Disinfection of <i>Escherichia coli</i> in ice by surface dielectric barrier discharge plasma. <i>Applied Physics Letters</i> , 2021, 119, 090601.	1.5	17
17	Parallel isolation of calicivirus and reovirus from lethal co-infected mink during a potential epidemic of farmed mink infections. <i>Biosafety and Health</i> , 2021, 3, 281-291.	1.2	3
18	SARS-CoV-2's origin should be investigated worldwide for pandemic prevention. <i>Lancet</i> , The, 2021, 398, 1299-1303.	6.3	19

#	ARTICLE	IF	CITATIONS
19	The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice. <i>Virologica Sinica</i> , 2021, 36, 1232-1235.	1.2	6
20	The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. <i>Nature</i> , 2020, 583, 830-833.	13.7	992
21	Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients. <i>Immunity</i> , 2020, 53, 685-696.e3.	6.6	299
22	Cold-chain transportation in the frozen food industry may have caused a recurrence of COVID-19 cases in destination: Successful isolation of SARS-CoV-2 virus from the imported frozen cod package surface. <i>Biosafety and Health</i> , 2020, 2, 199-201.	1.2	162
23	Excretion of SARS-CoV-2 through faecal specimens. <i>Emerging Microbes and Infections</i> , 2020, 9, 2501-2508.	3.0	45
24	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <i>Nature</i> , 2020, 584, 120-124.	13.7	1,237
25	Genomic characterization of SARS-CoV-2 identified in a reemerging COVID-19 outbreak in Beijing's Xinfadi market in 2020. <i>Biosafety and Health</i> , 2020, 2, 202-205.	1.2	26
26	A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. <i>Science</i> , 2020, 368, 1274-1278.	6.0	964
27	Development of an Inactivated Vaccine Candidate, BBIBP-CoV, with Potent Protection against SARS-CoV-2. <i>Cell</i> , 2020, 182, 713-721.e9.	13.5	639
28	Detection of SARS-CoV-2 in Different Types of Clinical Specimens. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1843-1844.	3.8	3,876
29	Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-CoV-2. <i>Science</i> , 2020, 368, 1016-1020.	6.0	1,537
30	A Novel Coronavirus from Patients with Pneumonia in China, 2019. <i>New England Journal of Medicine</i> , 2020, 382, 727-733.	13.9	21,542
31	Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. <i>Lancet</i> , The, 2020, 395, 565-574.	6.3	9,430
32	Age-related rhesus macaque models of COVID-19. <i>Animal Models and Experimental Medicine</i> , 2020, 3, 93-97.	1.3	238
33	Molecular Epidemiological, Serological, and Pathogenic Analysis of EV-B75 Associated With Acute Flaccid Paralysis Cases in Tibet, China. <i>Frontiers in Microbiology</i> , 2020, 11, 632552.	1.5	1
34	Convincing the confidence to conquer COVID-19: From epidemiological intervention to laboratory investigation. <i>Biosafety and Health</i> , 2020, 2, 185-186.	1.2	16
35	A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases in Wuhan, China 2019-2020. <i>China CDC Weekly</i> , 2020, 2, 61-62.	1.0	510
36	Description of the First Strain of 2019-nCoV, C-Tan-nCoV Wuhan Strain. <i>National Pathogen Resource Center, China</i> , 2020. <i>China CDC Weekly</i> , 2020, 2, 81-82.	1.0	23

#	ARTICLE	IF	CITATIONS
37	The Initial Case of COVID-19 “ Shulan City, Jilin Province, China, May 8, 2020. China CDC Weekly, 2020, 2, 458-459.	1.0	6
38	A Reemergent Case of COVID-19 “ Harbin City, Heilongjiang Province, China, April 9, 2020. China CDC Weekly, 2020, 2, 460-462.	1.0	5
39	Reemergent Cases of COVID-19 “ Xinfadi Wholesales Market, Beijing Municipality, China, June 11, 2020. China CDC Weekly, 2020, 2, 502-504.	1.0	30
40	Reemergent Cases of COVID-19 “ Xinjiang Uygur Autonomous Region, China, July 16, 2020. China CDC Weekly, 2020, 2, 761-763.	1.0	7
41	Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19). China CDC Weekly, 2020, 2, 123-124.	1.0	98
42	Description of the First Strain of 2019-nCoV, C-Tan-nCoV Wuhan Strain - National Pathogen Resource Center, China, 2020. China CDC Weekly, 2020, 2, 81-82.	1.0	10
43	Comprehensive Clinical and Laboratory Follow-up of a Female Patient With Ebola Virus Disease: Sierra Leone Ebola Virus Persistence Study. Open Forum Infectious Diseases, 2019, 6, ofz068.	0.4	12
44	Laboratory biosafety in China: past, present, and future. Biosafety and Health, 2019, 1, 56-58.	1.2	13
45	Clinical, immunological and bacteriological characteristics of H7N9 patients nosocomially co-infected by Acinetobacter Baumanni: a case control study. BMC Infectious Diseases, 2018, 18, 664.	1.3	8
46	Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone. Virologica Sinica, 2018, 33, 323-334.	1.2	7
47	Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses. MBio, 2018, 9, .	1.8	25
48	The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages. Emerging Microbes and Infections, 2017, 6, 1-7.	3.0	40
49	A47“Origin and possible genetic recombination of the middle east respiratory syndrome coronavirus from the first imported case in china: phylogenetics and coalescence analysis. Virus Evolution, 2017, 3, .	2.2	2
50	Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. Emerging Microbes and Infections, 2016, 5, 1-12.	3.0	24
51	Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. Journal of Infectious Diseases, 2016, 214, 1937-1946.	1.9	24
52	Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: Virological and clinical findings. Journal of Infection, 2016, 72, 52-59.	1.7	160
53	Genetic Diversity of Avian Influenza A (H10N8) Virus in Live Poultry Markets and Its Association with Human Infections in China. Scientific Reports, 2015, 5, 7632.	1.6	59
54	Poultry farms as a source of avian influenza A (H7N9) virus reassortment and human infection. Scientific Reports, 2015, 5, 7630.	1.6	50

#	ARTICLE	IF	CITATIONS
55	Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) from the First Imported MERS-CoV Case in China. <i>Genome Announcements</i> , 2015, 3, .	0.8	46
56	Origin and Possible Genetic Recombination of the Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China: Phylogenetics and Coalescence Analysis. <i>MBio</i> , 2015, 6, e01280-15.	1.8	86
57	Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. <i>Lancet, The</i> , 2014, 383, 714-721.	6.3	533